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ABSTRACT 
MOVING PSYCHOPATHOLOGY FORWARD: COMBINGING A TRANSDIAGNOSTIC 
AND DIMENSIONAL APPROACH TO CLINICAL ANXIETY, DEPRESSIVE, AND 
SUBSTANCE USE CONSTRUCTS 
Nicole Ashton Ricketts 
Western Carolina University (April 2017)  
 
The National Institute of Mental Health Research Domain Criteria (RDoC) initiative calls for 
systemic efforts to integrate neurobehavioral traits into dimensional models of psychopathology 
(Nelson et al., 2016). Examples are needed of how RDoC constructs can be linked to clinical 
symptoms. Thus, researchers evaluate two domains proposed by the RDoC model, Positive and 
Negative Valence System. Relevant MMPI-2-RF subscales, RC2 (Low Positive Emotion), RC7 
(Negative Emotionality), and DISC-r (Disconstraint) are used to examined the extent to which 
depressive, anxiety, and substance use disorders share underlying neurobehavioral constructs in 
2,873 inpatients and outpatients from the Minneapolis Veterans Affairs (VA) Medical Center and 
the Hennepin County Medical Center. Predictions were partially supported, clinical symptoms of 
depression and substance use overlap on neurobehavioral domains of positive valance, anxiety 
and substance use overlap on neurobehavioral domains of anxiety and substance use, however 
depression and anxiety did not overlap with cognitive systems. Results partially provide support 
for building a bridge between neurobehavioral constructs derived from neurophysiologic 
research (i.e., RDoC model) with core features of co-occurring psychopathology using a 
dimensional approach (MMPI-2-RF). With regards to inhibitory control (Cognitive Systems 
Domain), more research is needed to conceptualize INH as transdiagnostic.  
 
 
 
CHATPER 1: INTRODUCTION 
For several decades, little progress has been made to explain commonalities and 
distinctions in clinical psychopathology despite an established neurophysiological research 
literature which can move conceptualization of psychopathology forward. This is partly due to 
the outdated nosology, the Diagnostic and Statistical Manual (DSM; 2013), which defines 
psychopathology based on meeting symptom benchmarks that are defined by an appointed panel 
of professionals. The key problem with the DSM is that it separates disorders with the same 
underlying etiologies into different categories solely on the basis of  differing self-reported 
clinical symptoms (Sharp, Miller, & Heller, 2015) rather than on the basis of their pathology and 
etiology (Lilienfeld, 2014). This antiquated, symptom-based model may explain both the 
extensive co-occurrence among disorders and the lack of reliability and validity of 
psychopathological measurement in the DSM’s categorical approach.  
Due to increasingly apparent limitations of the DSM as a diagnostic tool and the growing 
discrepancy between DSM diagnoses and neurophysiology research, the National Institute of 
Mental Health has developed a system, Research Domain Criteria (RDoC), to transform current 
views of psychopathology into a system that is grounded in biological and psychological 
research, with an emphasis on “transdiagnosic components of psychopathology” (Sharp et al., 
2015, p. 365).Transdiagnostic components of psychopathology are conceptualized as 
“neurobehavioral traits” that reflect current biological and psychological findings (Sharp et al., 
2015). Using the RDoC domains, various neurobehavioral constructs which manifest across 
several disorders can be measured behaviorally as well as neurobiologically, creating a more 
integrated conceptualization of psychopathology. 
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This study is one of the first that investigates neurobehavioral domains set forth in the 
RDoC based on neurophysiology of depressive, anxiety, and substance use, and then utilizes 
these evidence-based domains (i.e., positive valance system and negative valence system) as a 
bridge to view clinical psychopathological constructs inclusively. In doing so, this study provides 
an initial effort to integrate the neurophysiologic “map” set forth by the RDoC with self-reported 
psychopathological constructs. 
The present goal of this project is to observe transdiagnostic components of 
psychopathology from the perspective of the RDoC model and translate these neurobehavioral 
findings into the clinical symptoms observed in co-occurring psychopathology, and evaluate 
these symptoms using the lens of a more valid, dimensional measure of clinical constructs 
associated with psychopathology.  
The goal of this study is to provide critical evidence that depression, anxiety, and 
substance use disorders co-occur largely due to common underlying neurophysiologic pathways. 
We propose that these pathways involve neural circuitry that generates positive and negative 
affect in the limbic system, and that the manifestation of clinical symptoms is determined by 
location and degree of frontal lobe involvement. By observing this marked overlap both in neural 
circuitry and in self-reported clinical symptoms, we suggest a novel explanation for the striking 
co-occurrence of common forms of psychopathology and an improved, more comprehensive 
neurobehavioral model for conceptualizing psychopathologic syndromes.  
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CHAPTER 2: LITERATURE REVIEW 
The following section reviews the relevant literature which forms the rationale for the 
proposed study. It will begin by describing the current debate over ways to define and diagnose 
psychopathology. In doing so, current categorical limitations of the DSM approach will be 
discussed, followed by an overview of how a dimensional approach to psychopathology yields 
more relevant data. For this reason, we will use a dimensional approach in this study. Since our 
theoretically-driven hypotheses also propose that unitary disorders, such as depression, anxiety, 
and substance use disorders share common underlying physiologic pathways, we will introduce 
the RDoC model and describe how using domains of this model relevant to the above-mentioned 
psychopathology provide the theoretical basis for understanding and translating neurobehavioral 
traits, focusing on positive valence and negative valence domains. Finally, we will provide the 
specific rationale and hypotheses for the current study, and the methods we propose to use. 
Categorical versus Dimensional Conceptualization of Psychopathology 
A current and critical issue in the field of clinical psychopathology is determining the 
most useful way to conceptualize psychopathology. The dilemma involves distinguishing 
between categorical and dimensional models of psychopathology (Haslam, Holland, & Kuppens, 
2011). The categorical model of conceptualizing and diagnosing psychopathology has been 
under scrutiny for quite some time (Zachar, 2013), yet it remains as the prevailing standard in the 
assessment of clinical diagnoses. In support of a categorical, or dichotomous, approach to 
diagnosis, Berenbaum (2013) asserts that classification approaches describe “objects of study in 
science and to serve as a source of concepts to be used within a scientific theory” (p. 894).  
For numerous decades, the categorical approach to psychopathology has been intricately 
connected with clinical psychology. For example, taxometric research methods have historically 
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played a major role in adoption of either a categorical approach to psychopathology or 
dimensional. Meehl and colleagues’ methodological work promoted researchers to “determine 
whether observed variation is underpinned by non-arbitrary latent class, or ‘taxon’, such as a 
discrete psychopathology” (Haslam et al., 2012, p. 903). Specifically, Meehl (1977) identified 
taxa as specific etiologies, much like discrete entities, whereas nontaxonic variables result from 
various influences. Establishing if a variable is better described as taxonic is fundamentally 
important in moving research forward.  
Research suggests that internalizing disorders, such as mood and anxiety disorders, as 
well as externalizing disorders are better described as nontaxonic variables that stem from 
several causal influences (Haslam et al., 2012). Researchers as well as clinicians acknowledge 
that categorical approaches to psychiatric disorders have been ineffective in moving science 
closer to understanding etiologies of mental disorders (Frances & Widiger, 2012).  Dimensional 
models of psychopathology have the ability to shift current classifications into a more 
empirically based and etiologically based nosology.   
In summary, much criticism has focused on its inability to defend apparently arbitrary 
distinctions between categories of psychopathology, and also that high frequencies of co-
occurring symptoms exist among different forms of psychopathology (Goekopp & Goekoop, 
2014). Recent research suggests no evidence for the continued use of the categorical approach to 
clinical diagnosis (Poland, 2015). Specifically, strict phenotypical separations that were 
presumed to occur between analogous categories have not been replicated in clinical reality 
(Goekopp & Goekoop, 2014). On the other hand, there is copious evidence suggesting pathways 
of psychopathology “involve causal processes that act both at micro levels and macro levels, that 
act within and outside of the individual, and that involve processes best understood from 
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biological, psychological, and sociocultural perspectives” (Kendler, 2008, p. 695). Thus, the 
preponderance of current research suggests that a dimensional approach to psychopathology may 
capture the underlying mechanisms and clinical symptoms of psychiatric disorders more 
effectively. Based on this evidence, the present study will measure psychopathological constructs 
using a continuous instrument (i.e, MMPI-2-RF) rather than the DSM-5 to capture the 
underlying common features of psychopathology. 
The DSM and its Limitations 
The Diagnostic and Statistical Manual (DSM) of mental disorders is one of the most 
extensively used referenced texts in the mental health field (American Psychiatric Association 
[APA], 2013). The latest edition, DSM-5, has amassed significant attention among researchers 
and clinicians (First, 2014). Rejoinders to revisions of the DSM, put forth by the DSM task force, 
have varied from fervent support (McCarron, 2013) to apprehensiveness (Welch, Klassen, 
Borisova, & Clothier, 2013) and even appeals to disband the use of the manual in its entirety  
(Frances & Widiger, 2012).  Advocates for the DSM argue that classification systems were 
designed primary for clinical purposes, particularly to provide a common language in the 
diagnosis and treatment of clients with mental health disorders, and developments in the 
treatment of mental health disorders have emerged from categorical classification systems 
(Casey et al., 2013).   
The most recent edition of the DSM includes updated clinical research from the past 20 
years in psychopathology, but it still fails to integrate highly informative and relevant advances 
in neuroscience and genetic research on the neurophysiological underpinnings of 
psychopathology that have emerged within the last several decades (Casey et al., 2013). Instead 
the DSM-5 continues to base diagnoses of psychopathology on self-reports of feelings and 
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experiences by clients, and on clinicians’ subjective interpretation of observed psychiatric signs 
and symptoms (First, 2014). Yet, clinicians continue to use the DSM despite its subjective 
interpretations, lack of empirical evidence, and inadequate integration of neurophysiological 
research. 
Emerging neurophysiologic and psychological literatures demonstrate that common 
neural pathology, etiology, and symptom clusters underlie traditionally distinct categories 
entities of psychiatric disorders (Cuthbert & Insel, 2010; Lilienfeld, 2014). Thus, many 
professionals were in hopes of a paradigm shift from categorical descriptive approaches to an 
approach that would be more dimensional focused that incorporated the advances in 
neuroscience (First, 2014).  There is no denying that classification systems have produced 
significant advances in the past; however, current research suggests a paradigm shift is needed in 
order to continue the advances in research and treatment for psychopathology. 
Comorbidity 
 Comorbidity of psychiatric disorders is a topic of major practical and theoretical 
significance and despite the vast amount of research conducted on co-occurring disorders, the 
reasons for high incidence of multiple diagnoses is largely unknown (Dell’Osso & Pini, 2012). 
Yet, with each successive revision of the DSM, an increase in the prevalence of psychiatric 
comorbidity occurs (Pincus, Tew, & First, 2004). Thus, the rarity of well described cases 
meeting criteria for only a single form of psychopathology indicates the need for fundamental 
changes in the way psychopathology is classified (Krueger & Markon, 2006). 
 Traditionally, psychopathology is a concept of descriptive and distinct categories, where 
categorical inclusion simply requires a sufficient number of presenting symptoms; countless 
combinations of symptoms are sufficient enough to receive diagnoses, as long as the presenting 
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number of symptoms is correct (Krueger & Markon, 2006). So, according to the categorical 
approach, psychopathology is simply an agreed upon number of signs and symptoms with a 
plethora of ways to meet diagnostic criteria.    
Based on this notion, research suggests that a large proportion of patients will 
concurrently meet diagnostic criteria for more than one diagnosis (Dell’Osso & Pini, 2012). 
Additionally, constancy of a diagnosis within individuals is relatively minimum; across 
clinicians individuals may actually meet criteria for a wide range of different disorders 
throughout their lifespan (Nolen-Hoeksema & Watkins, 2011). Therefore, if the comorbidity is 
greater than that expected by chance, as research suggests, the disorders are likely to be 
interrelated and perhaps the manifestation of the same etiological mechanism or the result of a 
shared influence (Dimaggio & Norcross, 2008).  For example, a client who misuses substances, 
has severe and recurrent depressive episodes, and has anxiety symptoms would receive three 
separate diagnoses as opposed to a single, all-inclusive diagnosis that might better capture the 
underlying common neural pathology, etiology, and symptoms (Pincus et al., 2004).  
Frequently co-occurring psychiatric disorders provides evidence against the notion that 
disorders represent discrete categorical entities. Conversely, any individual who meets the full 
diagnostics criteria for only one disorder may still have an increased frequency of symptoms 
from other categories, but fails to be diagnosed, and thus treated, due to the rigid confines of a 
categorical diagnostic system. Transdiagnostic approaches may explain co-occurring disorders 
by focusing on processes that are common across disorders and that causally contribute to 
underlying symptomology (Nolen-Hoeksema & Watkins, 2011). Thus, much evidence suggests 
that high rates of co-occurring disorders stem from shared underlying transdiagnostic 
mechanisms. 
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Reliability and Validity. A critical issue for both clinical decision making and clinical 
research advancement is the reliability of diagnosis (Regier et al., 2013). One of the major goals 
of the DSM-5 field trials was to produce a higher degree of inter-rater reliability among 
clinicians; however several of the most common psychiatric diagnoses failed to meet adequate 
thresholds of inter-rater reliability [e.g., depressive disorders (kappa .25-.34) and generalized 
anxiety disorder (kappa .34)]. Thus, if the diagnostic criteria defining a disorder in a given 
population cannot be measured consistently by two diagnosticians, then clients with those 
particular diagnoses cannot be expected to have common treatment response, or even similar 
etiological findings (Reiger et al., 2013). Consequently, greater attempts to improve reliability 
are called for.   
Disorders, such as autism spectrum, that were moved to a more dimensional approach in 
the DSM-5 demonstrated good to very good reliability (Reiger et al., 2013). Dimensional 
measures of psychopathology were 15% more reliable and 37% more valid than categorical 
measures across several constructs (Haslam et al., 2012); this provides strong support for a 
paradigm shift in the way professionals assess psychiatric symptoms. Proponents of the DSM-5 
as well as DSM-5 leaders compare diagnostic kappa values across medical setting and claim that 
most medical diagnose have comparable values; yet mental health professionals have expressed 
concerns regarding kappa values considering measures of inter-rater agreement were higher in 
the DSM-III (Ghaemi, 2013).  
The validity of current classifications of psychopathology has been questioned (Reiger, et 
al., 2013), since DSM categories do not map well onto emerging neuroscience and genetic 
research (Cuthbert & Insel, 2013). As a result, translating research into systematic ways of 
understanding psychopathology has become increasing difficult because it appears that 
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underlying symptom constellations cross current diagnostic boundaries, or are better 
conceptualized as “transdiagnostic” (Krueger & Eaton, 2015). As mentioned previously, in the 
absence of biomarkers, the majority of psychiatric disorders were based on clinical descriptions 
which resulted in official nosological groupings. However, research has indicated that the DSM-
5 groupings lack the ability to statistically predict crucial external benchmarks (Lilienfeld, 2014). 
For example, statistical analyses in one study detected patterns of comorbidity that suggested 
poor discriminant validity such that generalized anxiety disorder aligns more closely with mood 
disorders than with other anxiety disorders (Brown & Barlow, 2005). In line with these 
developments, a growing consensus among mental health care experts agree that the DSM, as the 
primary approach to clinical diagnosis of psychopathology, is a fundamentally flawed diagnostic 
tool which needs to be replaced for a host of compelling reasons, including the need to 
accurately characterize transdiagnostic symptom constellations.  
Moving Research Forwards: The RDoC Initiative 
The National Institute of Mental Health Research Domain Criteria Initiative (RDoC) is 
developing a new way to study psychopathology based upon dimensions of neurobiology and 
observable behavior (Casey, Oliveri, & Insel, 2014). The RDoC approach to psychopathology 
represents a much needed paradigm shift that conceptualizes psychopathology as dimensional 
rather than categorical model. This dimensional approach to psychopathology is based  on three 
core assumptions, which include:  1) psychiatric disorders are “disorders of brain circuits” 
(p.749), and 2) dysfunctions in neural circuitry can be detected by neuroscience devices, such as 
functional neuroimaging, and lastly that 3) information from genes will produce biomarkers that 
will improve clinical psychology (Insel & Cuthbert, 2010).  
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The RDoC matrix includes five general areas of function (e.g., negative valence, positive 
valence) and different levels of analysis including genetic, neural circuits, and self-report 
measures; all of these levels affect both the biology and psychology of psychiatric disorders 
(Cuthbert & Insel, 2013). The RDoC initiative is ultimately designed to provide a basis for 
integrating empirical data from various sources of neuroscience as a way to better understand 
underlying transdiagnostic mechanisms of psychopathology (Lilienfeld, 2014; National Insititue 
of Mental Health [NIMH], 2009). The current study proposes to do just this by examining how 
the positive and negative valance, and cognitive systems, three systems arguably most relevant in 
the RDoC model to psychopathology examined in this study, helps characterize the 
transdiagnostic symptoms of depression, anxiety, and substance use disorders.  
Negative Valence System 
As defined by the RDoC approach, the Negative Valance System domain is 
predominantly associated with responses to aversive conditions.  There are five constructs within 
this domain, which include; 1) responses to acute threat (fear); “the brain’s defensive 
motivational system to promote behaviors that protect the organism from perceived danger”, 2) 
potential harm (anxiety); activation of a specific brain area as a result of low probability threat 
behaviors, 3) sustained threat; aversive emotional conditions produced by sustained exposure to 
various internal and external circumstances that alter affect, cognition, physiology, and behavior 
even after the threat has subsided, 4) frustrative non-reward; consequences produced in response 
to the removal of reward, and 5) loss; “a state of deprivation of a motivationally significant con-
specific, object, or situation” and the reaction to loss may be episodic or chronic (NIMH, 2009). 
Based on this neurobehavioral description of the Negative Valence System, clinical symptoms 
associated with both anxiety and depression are readily apparent. Furthermore, the common 
 
 
11 
 
neural circuitry underlying the negative valence system is based on a strong foundation of 
translational research, and clearly requires a dimensional and transdiagnostic approach to 
understanding and characterizing psychopathological syndromes. 
Positive Valence System. The Positive Valance System, as defined by the RDoC 
approach, relates to positive motivational situations, such as reward seeking, and behavioral 
patterns that occur in response to a stimulus that elicits pleasurable reinforcement and learned 
behaviors. This domain includes five constructs; 1) approach motivation; “a multi-faceted 
construct involving mechanisms/processes that regulate the direction and maintenance of 
approach behavior influenced by pre-existing tendencies, learning, memory, stimulus 
characteristics, and deprivation states”, 2) initial responsiveness to reward; mechanisms related 
to pleasurable reactions, 3) sustained responsiveness to reward;  “processes associated with the 
termination of reward seeking”, 4) reward learning; a process of obtaining information about 
stimuli, actions, and contexts that are predictive of positive consequences, and how behavior is 
altered when novel rewards are presented (i.e., reinforced learning), and 5) habit; “sequential, 
repetitive, motor, or cognitive behaviors elicited by external or internal triggers that, once 
initiated, can go to completion without constant conscious oversight” (NIMH, 2009). The 
common neural circuitry underlying the Positive Valence Domain clearly reflects the clinical 
symptoms associated with both substance use and depression, and is also based on a strong 
foundation of transdiagnostic research that requires a dimensional approach to psychopathology.  
Cognitive Systems. The Cognitive Systems, as defined by the RDoC approach, relates to 
various cognitive processes. This domain includes five constructs; 1) Attention; “a range of 
processes that regulate access to capacity-limited systems”, 2) Perception; “process(es) that 
perform computations on sensory data to construct and transform representations of the external 
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environment, acquire information from, and make predictions about, the external world, and 
guide action”, 3) Declarative memory; which is responsible for encoding, storing, and retrieving 
information, 4) Language; a system of shared symbolic representations of the world, one’s self, 
and abstract thoughts that support communication, 5) Cognitive Control; a system that controls 
the operation of other cognitive and emotional systems in light of goal-directed behavior and 
when appropriate responses are needed to select from competing alternatives (NIMH, 2009). 
Based on RDoc descriptives and neuropsychological research, substance use also reflects this 
domain, particularly with the subconstruct of Response Selection; Inhibition/Suppression under 
the Cognitive Control construct. Inhibition/Suppression is focused on impulsive behaviors, such 
as substance use.  
MMPI-2-RF Clinical Scales: A Dimensional Measure of Psychopathology 
Rather than using a categorical approach to measuring neurobehavioral constructs set 
forth by the RDoC, the current study will use a more reliable and valid dimensional measure of 
psychopathological constructs. The most recent version of the MMPI, the MMPI-2-RF, includes 
restructured clinical (RC) scales to capture a dimensional approach to psychopathology. 
 The devolvement of the nine RC Scales used adequate samples sizes of male and female 
psychiatric inpatients and patients in substance use treatment (Tarescavage & Ben-Porath, 2014). 
Four strategic stages were used to develop the restructured scales; 1) isolate and measure the 
shared demoralization factor, 2) explore two to four factor solutions to identify at least one 
additional Core Clinical Scale besides the distinct demoralization factor, 3) to improve internal 
consistency and distinctiveness, core clinical scales were kept that resulted in both strong 
correlations with their core factors as well as weak correlation with the other previously 
identified core components (i.e., seed scales), and lastly, 4) by identifying the seed scales and 
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including items to the seed scales that demonstrated sound, distinctive, and sufficient 
associations with the particular scales, nine RC scales were developed resulting in 192 non-
overlapping items  (Tarescavage & Ben-Porath, 2014). The current study will focus on RC2- 
Low Positive Emotions, for measuring positive affect (PA), and RC7-Dysfunctional Negative 
Emotions, for negative affect (NA). 
Also in the revision of the MMPI-2, Harkness and McNulty revised their Personality 
Psychopathology-5 (PSY-5) Scale by undergoing a series of internal and external analyses 
(Tarescavage & Ben-Porath, 2014). The five broad personality traits, as measured by the PSY-5, 
are applicable to normal and abnormal functioning, and have been subjected to extensive 
examination by researchers in order to systematically move psychopathology toward 
dimensional models that clinicians and self-reports could understand (Harkness, Finn, McNulty, 
& Shields, 2012).  The MMPI-2-RF PSY-5 Scale includes a measure of inhibitory control (INH), 
Disconstraint-Revised (DISC-r), which is a focus of the current study.  
Low Positive Emotions (RC2) 
As described by Ben-Porath (2012), Low Positive Emotions (RC2), a lack of, or inability 
to experience positive emotions (anhedonia), has been associated as a core risk factor for 
depression across a wide range of settings and populations (i.e., inpatient and outpatient 
faculties, substance abuse treatment). An elevated score on RC2 is associated with an increased 
probability that the individual suffers from depressive symptoms (Ben-Porath, 2012). 
Specifically, researchers found depressive symptoms, such as anhedonia, loss of interest, 
decreased appetite and sleep, weakened concentration, depleted energy, suicide, and feelings of 
worthlessness or hopelessness to be correlated with RC2 in psychiatric inpatients (Arbisi, 
Sellbom, & Ben-Porath, 2008). In sum, an elevated score on RC2 (T score ≥ 65) has clinical 
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importance across a wide range of populations, settings, and psychiatric disorders when 
considering the core symptom, anhedonia.   
Dysfunctional Negative Emotions (RC7). According to Ben-Porath (2012), Tellegen 
hypothesized that positive affect and negative affect are “trait counterparts” (p.79), thus 
suggesting that high negative emotionality is correlated with anxiety-related psychopathology, 
while low positive emotionality is associated with depressive-related psychopathology. Negative 
Emotionality (RC7) is described as a “tendency to worry, be anxious, feel victimized and 
resentful, and appraise situations generally in ways that foster negative emotions” (Ben-Porath, 
2012, p. 79). Watson (2005) postulated that NA may account for the variance and comorbidity 
among distress and fear psychopathology. Elevated RC7 scores have been associated with 
various anxiety related disorders in psychiatric inpatients, veterans, as well as patients receiving 
treatment for substance use problems (Ben-Porath, 2012). Generally, negative emotionality is a 
core indicator of developing an anxiety related disorder.  
PSY-5 Disconstraint (DISC-r). Disconstraint (DISC-r), or inhibited self-control, tends to 
be associated with more risk-taking, impulsiveness, and excitement seeking behaviors, whereas 
low scores on DISC-r are associated with individuals who tend to follow the rules and are in 
general more inhibited people (Harkness, 2009). Elevated DISC-r scores have been associated 
with a wide array of externalizing problems, such as being diagnosed with a substance use 
disorder or having a history of substance misuse, juvenile delinquency, engaging in antisocial 
behaviors, domestic difficulties, problems with authority figures, and most notably, poor impulse 
control (Ben-Porath, 2015). These problems have been replicated in numerous settings such as, 
VA mental health and medical inpatient and outpatient facilities (Ben-Porath, 2012; Harkness et 
al., 2012). In addition, in a sample of National Guard soldiers, disconstraint scores were 
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associated with drinking and binge drinking frequency, quantity consumed in one sitting, and 
total yearly drinking (Harkness et al., 2012). DISC-r scores tend to been negatively correlated 
with an individual’s ability to sustain controlled behaviors.  
Mapping Clinical Constructs onto the RDoC Matrix: Neurophysiological Pathways 
Anxiety Constructs  
 Anxiety disorders are characterized by the clinical symptoms of excessive fear and 
avoidance, which are often a response to certain objects or situations even when true danger is 
absent, and collectively are among the most common disorders in the general population (Shin & 
Liberzon, 2010). Recent neuroimaging research has attempted to understand underlying brain 
circuits that may be related to the onset and maintenance of clinical anxiety symptoms. The 
accumulating evidence of common neural circuitry which underlie behavioral manifestations of 
anxiety led to its inclusion in the RDoC model. Specifically, given the nature of anxiety 
symptoms in conjunction with its purported underlying neural pathways, the RDoC matrix has 
conceptualized anxiety as a component of its Negative Valence Domain. The RDoC based its 
conclusion primarily on neuroimaging studies which examine anxiety at the level of neural 
circuitry, and concludes that excessive anxiety is produced by the inability to regulate negative 
emotional input within the overall cortical-limbic pathway (Martin, Ressler, Binder, & 
Nemeroff, 2009). 
  Although it is been well-established that the amygdala and its connections to the medial 
prefrontal cortex regulate the normal expression of both positive and negative emotions in many 
organisms (Kim et al., 2011), an excessive level of activity in parts of this circuitry in humans 
may relate to the manifestation of anxiety, which focuses specifically on the production of 
negative emotion and a simultaneous relative decrease in levels of activity in the mPFC, which 
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tend to regulate, or dampen down, negative emotion (Liotti et al., 2000). In general, this research 
has concluded the abnormality in this functional circuitry lies in the inability to successfully 
regulate negative emotional input from the amygdala by the mPFC, resulting in the expression of 
anxiety symptoms. 
 Emerging neuroimaging literature also shows that altered mPFC activity is associated 
with anxiety as well. Exact regions of the circuitry implicated between the amygdala and mPFC 
activity differ across studies. For instance, some studies have revealed that higher levels of 
anxiety are correlated with both decreased ventromedial prefrontal cortex (vmPFC) and 
increased dorsomedial prefrontal cortex (dmPFC), suggesting different functions for regions of 
the mPFC (Bishop, Duncan, Brett, & Lawrence, 2004). Recent research suggests that the 
interplay between the amygdala and mPFC that allows individuals to react to cues that predict 
threat as well as regulate the reactions when the environment is in need (Kim et al., 2011). For 
example, diffusion tensor imaging suggested that the strength of the shared connections in the 
amygdala and the mPFC is correlated with levels of anxiety; meaning the weaker the pathway, 
the higher the probability of anxiety (Graham & Milad, 2011). Collectively, evidence suggests 
dysfunctions in the mPFC, as well as the shared pathway of the amygdala and the mPFC, may 
account for the predisposition of anxiety disorders.  
The bed nucleus of the stria terminalis (BNST) has also been associated with increased 
anxiety; more precisely it plays a central role in sustained threat monitoring (Avery, Clauss, & 
Blackford, 2015). For instance, when compared to the control group, patients with anxiety 
disorders displayed hyperactivation of the BNST during an ambiguity gambling task, and the 
BNST is activated during hypervigilance in people higher trait anxiety (Adhikari, 2012). During 
fMRI scanning, activity in the BNST “continuously monitored changes in environmental threat 
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level and also subserved hypervigilant threat-monitoring processes in more highly trait anxious 
individuals” (Somerville, Whalen, & Kelley, 2010, p. 416). In sum, neuroimaging paradigms 
offer promising evidence for transdiagnostic mechanisms that underlie anxiety disorders.  
Depressive Constructs. The DSM-5 (2013) defines depressive disorders as the presence 
of sadness, emptiness, or irritable mood that are often accompanied by somatic and cognitive 
changes that result in significant impairment in one’s daily functioning. Depressive disorders are 
debilitating negative emotional states that may be related to dysfunctions in brain regions 
associated with emotional regulation (Seager, Rowley, & Ehrenreich-May, 2014) and 
abnormalities in neural reward circuity (Kujawa, Proudfit, & Klein, 2014). Given the clinical 
traits of depressive symptoms in conjunction with purported underlying neural pathways, we 
seek to integrate the literature on neural circuitry in depression with specific reference to the 
RDoC’s Positive Valence Domain.  
Depression should be conceptualized as a “multidimensional, systems-level disorder 
affecting discrete, but functionally integrated, pathways” (Mayberg, 2003, p. 194); which may 
affect the brain’s capacity to sustain homeostatic emotional regulation during times of intensified 
cognitive and somatic stress (Zeng et al., 2012). Specifically, neuroimaging studies purport that 
limbic pathways are dysregulated in depression as well as altered activity in the prefrontal 
cortical regions and amygdala (Sliz & Hayley, 2012), which, as mentioned above, are the same 
neural circuitry that tends to be involved in anxiety.  
Heightened negative affect describes anxiety and depression; however, anhedonia is 
central to depression, and anxiety is highly correlated with an increased concern over uncertain 
situations (Dillion et al., 2014). Anhedonia and reward processing is associated with 
dysfunctions in the medial orbitofrontal cortex (mOFC), vmPFC, and the amygdala; 
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abnormalities in these neural reward circuits may also be a crucial feature underlying depressive 
disorders (Dillion et al., 2014). Functional MRI studies have revealed that depressed individuals 
display decreased activation in reward circuits of the brain (i.e., mOFC, vmPFC, amygdala) and 
are less apt to regulate their behavior in response to rewards; left frontal asymmetry was also 
found in depressed individuals’ EEGs, reflecting low approach-related motivation to rewards 
(Kujawa et al., 2014). Therefore, suggesting that abnormalities in response to reward may be a 
vulnerability marker of depression.   
Functional imaging studies implicate the ventromedial (vmPFC) and dorsolateral (dlPFC) 
areas of the prefrontal cortex as key neural substrates underlying depression; specifically, 
hyperactive  vmPFC plays a role in the generation of negative affect, and dlPFC hypoactivity is 
associated with cognitive control functions that may also pertain to emotions (Koenigs & 
Grafman, 2009). Depression has also been associated with abnormalities in the amygdala, 
particularly decreased amygdala volume (Siegle, Thompson, Carter, Steinhauer, & Thase, 2007). 
The amygdala has also been shown to play a role in identifying emotionally significant stimuli, 
as well as the recollection of emotionally meaningful events; depressed individuals show greater 
amygdala reactivity to emotional stimuli (Gotlib & Hamilton, 2008). Accordingly, dysfunctions 
in the prefrontal cortex, as well as common pathways of the amygdala may account for an 
individual’s susceptibility to depressive disorders.  
Substance Use Constructs. According to the DSM-5 (2013), the critical facet of a 
substance use disorder (SUDs) is a constellation of cognitive, behavioral, and physiological 
symptoms indicating that the individual continues to use the desired substance despite significant 
substance use consequences. A cardinal trait of SUDs is the “excessive pursuit and use of a 
substance that is disproportionate to the hedonic impact derived from it” (Baskin-Sommers & 
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Foti, 2015, p. 230). Different types of substances have different pharmacological and 
pharmacokinetic properties, but all substances share a common neural dysfunction, reward 
circuitry (Baskin-Sommers & Foti, 2015). In addition to cardinal feature of decreased sensitivity 
to reward, SUDs are also related to impaired emotional regulation, and inhibitory control 
(Franken & van de Wetering, 2015; Gorka, Chen, & Daughters, 2015) and much research has 
focused on brain reward systems and altered circuity functioning to better understand the 
etiology of SUDs (Lindberg, Fugett, & Carter, 2015). Specifically, SUDs neuroimaging findings 
should be organized with respect to key reward constructs within the Positive Valence and 
Cognitive System Domain.   
 Recently, key neural circuitry associated with SUDs (Baskin-Sommers & Foti, 2015) has 
been identified, including the frontal-limbic system, specifically the orbitofrontal cortex (OFC), 
and amygdala (Brady & Sinha, 2005), suggesting that an interactive networks of neural circuitry 
underlies substance use disorders. 
 Substance use disorders are associated with reduction in reward responsiveness, 
particularly to pleasant stimuli that are not drug related, which may be associated to anhedonia in 
depression (Gearhardt, Boswell, & Potenza, 2014). Traditionally, neuroimaging has focused on 
dysregulation in frontal-limbic systems associated with reward pathways in substance use 
disorders; including reduced frontal metabolism and hypoactivity in the amygdala, which have 
also been purported in depressive disorders (Brady & Sinha, 2005). In regards to reward 
pathways, the importance in the PFC has increased; specifically the OFC, which is involved in 
inhibitory decision making, especially in reward-related behaviors; decreases in the PFC are also 
implicated in deficits in inhibitory control, also a key clinical trait of SUDs (Dom, Sabbe, 
Hulstijn, & Van Den brink, 2005). Withregard to emotional regulation and inhibitory control, 
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reduced activity in the amygdala, dPFC, and vmPFC is associated with substance misuse 
(Gearhardt et al., 2014).  In sum, dysfunctions in the prefrontal cortex and limbic systems may 
account for the vulnerability to development a substance use disorder.  
Shared Transdiagnostic Constructs. The clinical symptoms of anxiety, depressive, and 
substance use disorders are extensive, involving emotional, motivational, cognitive and 
neurophysiological domains. Depression frequently co-occurs with anxiety, and it has been 
estimated that over half of individuals with a depressive or anxiety disorder also meet diagnostic 
criteria for a substance use disorders and, conversely, approximately half of individuals suffering 
from substance use disorders have co-occurring depressive or anxiety disorders, which suggests 
a significant degree of overlap among specific brain regions (Russo & Nestler, 2013). From a 
neurophysiological perspective, individuals with these disorders display dysfunctions in the 
cortical-limbic system and reward circuity. 
Differential activation patterns in the brain’s reward circuitry have been associated with 
negative emotional symptoms that often accompany clinical symptoms of depression, anxiety, 
and substance use disorders. More precisely, associations between self-reports of emotional 
states and metabolism in limbic regions have been identified across disorders (Volkow, 2004). 
The brain areas and neural circuitry most frequently identified as dysregulated across disorders 
are cortical regions of prefrontal cortex and the amygdala (Ressler & Mayberg, 2007; Peters, 
Kalivas, & Quirk, 2009). In general, a dysfunction in the cortical-limbic system and reward 
circuity could conceivably predispose an individual to an anxiety, depressive, and substance use 
disorder. For this reason, it is likely that current clinical nosology of psychopathological 
phenomena is not identifying the more “authentic” phenotypic clusters of overlapping disorders, 
and, in turn, may not be most useful system to move psychopathology forward.  
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Purpose 
The National Institute of Mental Health’s Research Domain Criteria Initiative (RDoC) 
calls for systematic efforts to integrate neurobehavioral traits into dimensional models of 
psychopathology (Nelson et al., 2016). Current RDoC findings suggest that common neural 
etiologies underlie traditionally distinct forms of psychopathology and should be better 
conceptualized as transdiagnostic (Insel & Cuthbert, 2010; Lilienfeld, 2014). Yet additional 
empirical examples are needed to link biobehavioral constructs to clinical symptoms (Nelson et 
al., 2016). Thus, the current study will evaluate two domains proposed by the RDoC model, 
Positive and Negative Valence System, to further provide empirical evidence for the extent to 
which depression (DEP), anxiety (ANX), and substance use disorders (SUDs) share underlying 
neurobehavioral constructs by using a dimensional approach to psychopathology. Our 
dimensional approach, the MMPI-2-RF, will allow us to accomplish our goal using the most 
empirically-validated and reliable measure of psychopathology in the literature. 
Hypotheses 
 The present study will explore the associations of the RDoC’s neurobehavioral 
constructs of Positive Valence, Negative Valence, and Cognitive Systems with clinical 
symptoms of frequently co-occurring syndromes identified by the DSM-IV.  Specifically, we 
will examine the extent to which depressive symptoms (DEP), anxiety symptoms (ANX), and 
symptoms of substance use disorders (SUDs) share these underlying neurobehavioral constructs 
using the dimensional approach of the MMPI-2-RF. We will measure relevant MMPI-2-RF 
subscales, RC2 (Low Positive Emotion), RC7 (Negative Emotionality), and DISC-r 
(Disconstraint), from an archival data set comprised of veteran and non-veteran inpatients. In 
line with recent theory advocating a transdiagnostic approach to conceptualizing 
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psychopathology, we expect to see overlapping clinical symptoms across our three groups, and 
we also expect these overlapping symptoms will reflect the neurobehavioral domains of positive 
and negative valence, and cognitive systems from the RDoC model. Results from this 
investigation may provide greater support for building a bridge between neurobehavioral 
constructs derived from neurophysiologic research (i.e., RDoC model) with core features of co-
occurring psychopathology using a dimensional approach (MMPI-2-RF).  
Specifically, the following hypotheses will be examined in our sample: 
Hypothesis 1: Researchers will demonstrate that SUDs overlap with DEP on core underlying 
neurobehavioral trait constructs of positive affect (PA), as set forth by the RDoC approach and 
measured by the MMPI-2-RF Restructured Clinical Scales RC2. We expect that: 
 PA, as measured with reversed directionality by RC2, will not differ between DEP only and 
DEP and SUD 
 
Hypothesis 2: Researchers will demonstrate that SUDs overlap with ANX on core underlying 
neurobehavioral trait constructs of negative affect (NA), as set forth by the RDoC approach and 
measured by the MMPI-2-RF Restructured Clinical Scales RC7. We expect that: 
NA, as measured by RC7, will not differ between ANX only and ANX and SUD 
 
Hypothesis 3: Researchers will demonstrate that SUDs overlap with DEP and ANX on core 
underlying neurobehavioral trait constructs of INH, as set forth by the RDoC approach and 
measured by the MMPI-2-RF PSY-5 Scales DISC-r. We expect that: 
A: INH, as measured by DISC-r, will not differ between DEP only vs. DEP and SUD. 
B: INH, as measured by DISC-r, will not differ between ANX only vs. ANX and SUD.  
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C: Patients who score higher on DISC-r, may be more likely to also have SUD.  
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CHAPTER 3: METHOD 
Participants 
  The data set that will be used for analyses is comprised of 2,873 inpatients and 
outpatients from the Minneapolis Veterans Affairs (VA) Medical Center and the Hennepin 
County Medical Center who completed the MMPI-2, which was converted into MMPI-2-RF, and 
received DSM-III or DSM-IV diagnoses as part of their comprehensive psychological 
assessment. The majority of are males (75.5%) with a mean age of 40.13 (SD = 4.018) years. The 
ethnic composition of the data set is as follows: 78.6% were Caucasian, 15.4% African 
American, 1.8 Native American, 1.1% Asian American, 1.0% Hispanic, and 1.3% other. 
Measures. MMPI-2-RF. The 338-item Minnesota Multiphasic Personality Inventory-2-
Restructured Form is a true/false, self-report inventory that was developed conceptually and 
empirically to assesses an individual’s psychological functioning across several domains (i.e., 
personality, psychopathology, and social/behavioral functioning) (Tellegen & Ben-Porath, 2008) 
.The MMPI-2-RF contains a total of 51 scales, 9 Validity Scales, and 42 substantive scales, and 
for the purposes of this study we will focus on RC2; Low Positive Emotion, RC7; Dysfunctional 
Negative Emotions, and DISC-r; Discontraint-Revised. Reliability of the proposed RC Scales 
include: RC2; .84 for men and .82 for women in outpatient community mental health centers, .86 
for men and women in psychiatric inpatient community hospitals, and .84 for men in psychiatric 
inpatient VA hospitals, RC7: .87 for men and women in outpatient community mental health 
centers, .90 for men and .89 for women in psychiatric inpatient community hospitals, and .89 for 
men in psychiatric inpatient VA hospitals (Tellegen & Ben-Porath, 2008). Reliability of the 
MPPI-2-RF Personality Psychopathology five (PSY-5) Scale, DISC-r, is .72 for men and .70 for 
women in outpatient community mental health centers, .73 for men and women in psychiatric 
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inpatient community hospitals, and .75 for men in psychiatric inpatient VA hospitals (Tellegen & 
Ben-Porath, 2008). Specifically, the MMPI–2-RF technical manual offers extensive reliability 
and validity data for this instrument (Tellegen & Ben-Porath, 2008). Higher scores on DISC-r 
indicate greater disinhibitory control, or INH-.  Higher scores on RC2, or PA-, represent a lack of 
positive emotion, and RC7 (NA-) indicates a tendency to be worried or anxious (Ben-Porath, 
2012).  
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CHAPTER FOUR: RESULTS 
Hypothesis 1: Researchers will demonstrate that SUDs overlap with DEP on core 
underlying neurobehavioral trait constructs of positive affect (PA), as set forth by the 
RDoC approach and measured by the MMPI-2-RF Restructured Clinical Scales RC2. We 
expect that: 
PA, as measured with reversed directionality by RC2, will not differ between DEP only and 
DEP and SUD 
An independent-samples t-test was conducted to compare RC2 in co-occurring DEP and SUD 
and DEP only. There was not a significant difference in the scores for DEP and SUD (M = 69.94, 
SD = 15.52) and DEP only (M = 69.58, SD = 16.35); t(1319) = -.40, p = .687  
The DEP and SUD (n = 613) group was comprised of 79.1% males and 20.9% females with a 
mean age of 38.6 and the DEP (n = 708) only group was 68.6% male and 31.4% female with a 
mean age of 41.4.  
Hypothesis 2: Researchers will demonstrate that SUDs overlap with ANX on core 
underlying neurobehavioral trait constructs of negative affect (NA), as set forth by the 
RDoC approach and measured by the MMPI-2-RF Restructured Clinical Scales RC7. We 
expect that: 
NA, as measured by RC7, will not differ between ANX only and ANX and SUD 
 An independent-samples t-test was conducted to compare RC7 in co-occurring ANX and SUD 
and ANX only. There was not a significant difference in the scores for ANX and SUD (M = 
65.11, SD = 14.22) and ANX only (M = 63.67, SD = 15.06); t(82) = -.45, p = .657 
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The ANX and SUD (n = 36) group was comprised of 75% males and 25% females with a mean 
age of 40.3 and the ANX (n = 48) only group was 75% male and 25% female with a mean age of 
44.1. 
Hypothesis 3: Researchers will demonstrate that SUDs overlap with DEP on core 
underlying neurobehavioral trait constructs of INH, as set forth by the RDoC approach 
and measured by the MMPI-2-RF PSY-5 Scales DISC-r. We expect that: 
A: INH, as measured by DISC-r, will not differ between DEP only vs. DEP and SUD. 
An independent-samples t-test was conducted to compare DISC-r in co-occurring DEP and SUD 
and DEP only. There was a significant difference in the scores for DEP and SUD (M = 61.02, SD 
= 11.47) and DEP only (M = 53.65, SD = 11.41); t(1319) = -11.68, p < .001 
B: INH, as measured by DISC-r, will not differ between ANX only vs. ANX and SUD.  
An independent-samples t-test was conducted to compare DISC-r in co-occurring ANX and SUD 
and ANX only. There was a significant difference in the scores for ANX and SUD (M = 60.67, 
SD = 12.46) and ANX only (M = 52.23, SD = 9.54); t(82) = -3.52, p < .001 
C: Patients who score higher on DISC-r, may be more likely to also have SUD.  
An independent-samples t-test was conducted to compare DISC-r in SUD and no SUD. There 
was a significant difference in the scores for SUD (M = 61.28, SD = 11.49) and no SUD (M = 
53.99, SD = 11.21); t(2871) = -17.021, p < .001 
The SUD (n = 649) group was comprised of 78.9% males and 21.1% females with a mean age of 
38.7 and the no SUD (n = 756) only group was 69% male and 31% female with a mean age of 
41.5.  
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CHAPTER FIVE: DISCUSSION 
The purpose of this study was to provide systematic efforts to integrate neurobehavioral 
traits into dimensional models of psychopathology that correspond to constructs of Positive and 
Negative Valence, and Cognitive Systems as set forth by the NIMH’s RDoC initiative.More 
specifically, this study attempted to demonstrated that core neurobehavioral traits overlapped 
with clinical symptoms with regards to depression (DEP), anxiety (ANX), and substance use 
disorders (SUDs) using the most empirically-validated and reliable measure of psychopathology 
in the literature, the MMPI-2-RF. These findings did not provide evidence for viewing SUD as 
transdignostic.  However, and with regards to the current findings, limitations, and future 
research is discussed in order to further advance research and shift current categorical 
taxonomies to a more empirically and etiologically based nosology of psychopathology.  
With regards to PA, as measured with reversed directionality by RC2, the relationship 
was as predicted; individuals diagnosed with a depressive disorder alone did not differ from co-
occurring depressive and substance use disorder on measures of positive affect. Individuals 
diagnosed with a depressive disorder did not score lower on levels of PA than individuals with 
co-occurring DEP and SUD. This is in line with neuroscientific work showing that depressive 
symptoms may not be discrete emotional states from substance use disorders.  
 Researchers demonstrated that the association between individuals diagnosed with an 
anxiety disorder alone and co-occurring anxiety substance use disorder on measures of negative 
affect was not significant. That NA showed no differential relation between ANX and ANX and 
SUD is not surprising in light of pervious neurophysiological research which purports that 
individuals with these disorders display dysfunctions in the cortical-limbic system and reward 
circuity, and high co-occurrence rates (Russo & Nestler, 2013).  
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However, differential patterns of association were evident for two constructs in relations 
to INH; individuals diagnosed with a depressive disorder differed from individuals with a co-
occurring depressive and substance use disorder, this pattern of associations was also seen with 
anxiety disorders versus co-occurring anxiety and substance use disorder. Research has 
established that dysfunctions in the connectivity between amygdala and the vmPFC may increase 
susceptibility to anxiety and depressive disorders (Motzkin et al., 2014). However, the exact 
processes by which the vmPFC influences affective processing are not entirely understood. Yet, 
it is proposed that the vmPFC serves to regulate negative affect by “top-down inhibition” of 
brain regions involved in processing negative emotion, mainly the amygdala. Thus, clinically 
elevated levels of negative affect in depressive and anxiety disorders develop due to 
dysregulations in the vmPFC and interconnected amygdala activity (Motzkin et al., 2014). As 
mentioned before, the vmPFC has been implicated as a critical component of decision making. It 
is well documented in neuropsychological research that areas of the brain implicated in decision 
making influence levels of inhibitory control (Boes et al., 2009). Hence, patients with 
dysregulated vmPFC display an impaired ability to weigh risks and benefits effectively. And 
recent advances in neuroimaging techniques have shown that substance use has been shown to 
further impair the vmPFC (Boes et al., 2009), thus exacerbating weak inhibitory control. 
Consequently, when a patient lacks vmPFC regulation of the amygdala as a result of co-
occurring substance use, there is an increased activation in the amygdala possibly accounting for 
the differences in co-occurring SUD and DEP or ANX. In line with this inhibitory model of 
vmPFC function, SUD, ANX, and DEP symptoms may share common circuity, yet the extent to 
which the vmPFC modulates amygdala function may differ.  Hence, the exact processes by 
which the vmPFC influences the amygdala across disorders is warranted before conceptualizing 
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SUD as “transdiagnostic.”  Considering INH showed differential patterns of associations across 
clinical symptoms with regards to depressive, anxiety, and substance use problems. 
 Some limitations of the present study should be addressed when considering the 
implications of the findings. First, variables were based on self-reports and DSM-III or DSM-IV 
diagnoses. It will be important in future research for clinicians and researchers to replicate these 
findings based on clinical presentation and symptomology in order to provide information 
beyond DSM diagnoses. This will aid in providing more ideal treatments modalities for 
‘disorders’ that may share common neural circuitry. It will be important to operationalize INH in 
other ways, not only by self-report measures, or clinician rating, but in physiological (EEG), 
neurological measures (fMRI), and other behavioral measures (Go-NoGo task) as well. 
Comparing self-report assessments and/or clinician rating to fMRIs findings may provide even 
more fruitful information to better understand the gap between DSM categories and emerging 
neuroscience. Also given the number of statistical tests performed, it will be important to see if 
findings differ in new samples. It is important to note that this sample is comprised of mostly 
middle age, white males, and thus a sample with broader demographics would further provide 
generalizability.  
Aside from the limitations, the current findings have important implications 
diagnostically and for neuroscientific research that focuses on understanding the extent to which 
neurobehavioral constructs are shared across depressive, anxiety, and substance use. These 
findings suggest that inhibitory control plays a critical role in patients that pathologically use 
substance. Lower levels of INH could denote a distinct pathophysiological process in patients 
who are diagnosed with a substance use ‘disorder.’  Moreover, research postulates that the 
cardinal feature of a SUD is the decreased sensitivity to reward, however behavioral 
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dysregulation related to unconstrained behavior (poor inhibitory control) may play a more vital 
role in clinically elevated substance use. With regards to treatment, impaired inhibitory control 
leads to using more of a substance than intended, and failed attempts to control one’s use. 
Clinically elevated levels of inhibitory control have also been correlated with a significant risk 
for treatment noncompliance and an unlikelihood that the patient will be internally motivated to 
seek treatment (Tellegen & Ben-Porath, 2008). Hence, inadequate impulse control as the target 
of treatment may increase attempts in controlling substance use, preventing relapse, and increase 
overall noncompliance. It will be important to continue to explore the role of INH as well as 
other possible transdiagnostic traits with regards to DEP, ANX, and SUD given the common 
neural circuitry. Globally, systematic efforts that integrate neurobehavioral traits can move 
psychopathology toward a more etiological based conceptualization of psychopathology that 
assess across clinical symptoms.  
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